Kurt D Ristroph1, Jie Feng1, Simon A McManus1, Yingyue Zhang1, Kai Gong2,3, Hanu Ramachandruni4, Claire E White2,3, Robert K Prud'homme5. 1. Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08854, USA. 2. Department of Civil and Environmental Engineering, Princeton University, Princeton, NJ, 08854, USA. 3. Andlinger Center for Energy and the Environment, Princeton University, Princeton, NJ, 08854, USA. 4. Medicines for Malaria Venture, Route de Pré-Bois 20, 1215, Meyrin, Switzerland. 5. Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08854, USA. prudhomm@princeton.edu.
Abstract
BACKGROUND: OZ439 is a new chemical entity which is active against drug-resistant malaria and shows potential as a single-dose cure. However, development of an oral formulation with desired exposure has proved problematic, as OZ439 is poorly soluble (BCS Class II drug). In order to be feasible for low and middle income countries (LMICs), any process to create or formulate such a therapeutic must be inexpensive at scale, and the resulting formulation must survive without refrigeration even in hot, humid climates. We here demonstrate the scalability and stability of a nanoparticle (NP) formulation of OZ439. Previously, we applied a combination of hydrophobic ion pairing and Flash NanoPrecipitation (FNP) to formulate OZ439 NPs 150 nm in diameter using the inexpensive stabilizer hydroxypropyl methylcellulose acetate succinate (HPMCAS). Lyophilization was used to process the NPs into a dry form, and the powder's in vitro solubilization was over tenfold higher than unprocessed OZ439. METHODS: In this study, we optimize our previous formulation using a large-scale multi-inlet vortex mixer (MIVM). Spray drying is a more scalable and less expensive operation than lyophilization and is, therefore, optimized to produce dry powders. The spray dried powders are then subjected to a series of accelerated aging stability trials at high temperature and humidity conditions. RESULTS: The spray dried OZ439 powder's dissolution kinetics are superior to those of lyophilized NPs. The powder's OZ439 solubilization profile remains constant after 1 month in uncapped vials in an oven at 50 °C and 75% RH, and for 6 months in capped vials at 40 °C and 75% RH. In fasted-state intestinal fluid, spray dried NPs achieved 80-85% OZ439 dissolution, to a concentration of 430 µg/mL, within 3 h. In fed-state intestinal fluid, 95-100% OZ439 dissolution is achieved within 1 h, to a concentration of 535 µg/mL. X-ray powder diffraction and differential scanning calorimetry profiles similarly remain constant over these periods. CONCLUSIONS: The combined nanofabrication and drying process described herein, which utilizes two continuous unit operations that can be operated at scale, is an important step toward an industrially-relevant method of formulating the antimalarial OZ439 into a single-dose oral form with good stability against humidity and temperature.
BACKGROUND:OZ439 is a new chemical entity which is active against drug-resistant malaria and shows potential as a single-dose cure. However, development of an oral formulation with desired exposure has proved problematic, as OZ439 is poorly soluble (BCS Class II drug). In order to be feasible for low and middle income countries (LMICs), any process to create or formulate such a therapeutic must be inexpensive at scale, and the resulting formulation must survive without refrigeration even in hot, humid climates. We here demonstrate the scalability and stability of a nanoparticle (NP) formulation of OZ439. Previously, we applied a combination of hydrophobic ion pairing and Flash NanoPrecipitation (FNP) to formulate OZ439 NPs 150 nm in diameter using the inexpensive stabilizer hydroxypropyl methylcellulose acetate succinate (HPMCAS). Lyophilization was used to process the NPs into a dry form, and the powder's in vitro solubilization was over tenfold higher than unprocessed OZ439. METHODS: In this study, we optimize our previous formulation using a large-scale multi-inlet vortex mixer (MIVM). Spray drying is a more scalable and less expensive operation than lyophilization and is, therefore, optimized to produce dry powders. The spray dried powders are then subjected to a series of accelerated aging stability trials at high temperature and humidity conditions. RESULTS: The spray dried OZ439 powder's dissolution kinetics are superior to those of lyophilized NPs. The powder's OZ439 solubilization profile remains constant after 1 month in uncapped vials in an oven at 50 °C and 75% RH, and for 6 months in capped vials at 40 °C and 75% RH. In fasted-state intestinal fluid, spray dried NPs achieved 80-85% OZ439 dissolution, to a concentration of 430 µg/mL, within 3 h. In fed-state intestinal fluid, 95-100% OZ439 dissolution is achieved within 1 h, to a concentration of 535 µg/mL. X-ray powder diffraction and differential scanning calorimetry profiles similarly remain constant over these periods. CONCLUSIONS: The combined nanofabrication and drying process described herein, which utilizes two continuous unit operations that can be operated at scale, is an important step toward an industrially-relevant method of formulating the antimalarial OZ439 into a single-dose oral form with good stability against humidity and temperature.
Entities:
Keywords:
Artefenomel; Drug delivery; Drug solubilization; Flash NanoPrecipitation; Hydrophobic ion pairing; Malaria; Nanocarrier; OZ439; Oral therapeutic; Spray drying
Authors: Joerg J Moehrle; Stephan Duparc; Christoph Siethoff; Paul L M van Giersbergen; J Carl Craft; Sarah Arbe-Barnes; Susan A Charman; Maria Gutierrez; Sergio Wittlin; Jonathan L Vennerstrom Journal: Br J Clin Pharmacol Date: 2013-02 Impact factor: 4.335
Authors: James S McCarthy; Mark Baker; Peter O'Rourke; Louise Marquart; Paul Griffin; Rob Hooft van Huijsduijnen; Jörg J Möhrle Journal: J Antimicrob Chemother Date: 2016-06-05 Impact factor: 5.790
Authors: Jeremy N Burrows; Stephan Duparc; Winston E Gutteridge; Rob Hooft van Huijsduijnen; Wiweka Kaszubska; Fiona Macintyre; Sébastien Mazzuri; Jörg J Möhrle; Timothy N C Wells Journal: Malar J Date: 2017-01-13 Impact factor: 2.979
Authors: Jie Feng; Yingyue Zhang; Simon A McManus; Kurt D Ristroph; Hoang D Lu; Kai Gong; Claire E White; Robert K Prud'homme Journal: ACS Appl Nano Mater Date: 2018-04-20
Authors: Rick M Fairhurst; Gaurvika M L Nayyar; Joel G Breman; Rachel Hallett; Jonathan L Vennerstrom; Socheat Duong; Pascal Ringwald; Thomas E Wellems; Christopher V Plowe; Arjen M Dondorp Journal: Am J Trop Med Hyg Date: 2012-08 Impact factor: 2.345
Authors: Jie Feng; Chester E Markwalter; Chang Tian; Madeleine Armstrong; Robert K Prud'homme Journal: J Transl Med Date: 2019-06-14 Impact factor: 5.531